title: Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
abstract: Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States. There is a 3-fold increase in the prevalence of coronary heart disease, myocardial infarction, and stroke due to the coagulation, hemodynamic, and metabolic abnormalities seen in these individuals. The use of aspirin for secondary prevention and, to a lesser degree, primary prevention of cardiovascular events is a well-established standard of care. However, in patients with diabetes or the cardiometabolic syndrome, the role of aspirin in prevention of cardiovascular events remains controversial. In this review, the authors examine the clinical trial data on the use of aspirin in diabetes and the cardiometabolic syndrome for cardiovascular protection. They also explore, in addition to aspirin's effects on platelet aggregation, some of the mechanisms by which aspirin may favorably alter the course of atherosclerosis, effects on endothelial function, and glycemia.
authors.affiliation: Diabetes and Cardiovascular Center, University of Missouri School of Medicine and Truman VA Hospital, Columbia, MO 65212, USA. gardnermj@health.missouri.edu
authors.forename: Michael
authors.initials: M
authors.lastname: Gardner
authors.forename: John
authors.initials: J
authors.lastname: Palmer
authors.forename: Camila
authors.initials: C
authors.lastname: Manrique
authors.forename: Guido
authors.initials: G
authors.lastname: Lastra
authors.forename: David W
authors.initials: DW
authors.lastname: Gardner
authors.forename: James R
authors.initials: JR
authors.lastname: Sowers
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D002317:Cardiovascular Agents; D001241:Aspirin